Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial

Objective: Risperidone has demonstrated efficacy for acute (8 week) and intermediate length (6 month) management of severe irritability and aggression in children and adolescents with autism. Less is known about the long-term effects of risperidone exposure in this population. We examined the tolera...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:J Child Adolesc Psychopharmacol
Główni autorzy: Aman, Michael, Rettiganti, Mallikarjuna, Nagaraja, Haikady N., Hollway, Jill A., McCracken, James, McDougle, Christopher J., Tierney, Elaine, Scahill, Lawrence, Arnold, L. Eugene, Hellings, Jessica, Posey, David J., Swiezy, Naomi B., Ghuman, Jaswinder, Grados, Marco, Shah, Bhavik, Vitiello, Benedetto
Format: Artigo
Język:Inglês
Wydane: Mary Ann Liebert, Inc. 2015
Hasła przedmiotowe:
Original Articles
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4545698/
https://ncbi.nlm.nih.gov/pubmed/26262903
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/cap.2015.0005
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy